Cytopag 50 mg (Tablet)
Unit Price: ৳ 900.00 (1 x 5: ৳ 4,500.00)
Strip Price: ৳ 4,500.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Eltrombopag olamine |
| Company | Aci limited |
| Also available as |
Indications
- Treatment of thrombocytopenia in patients with persistent or chronic immune thrombocytopenia
- Treatment of thrombocytopenia in patients with hepatitis C infection
- Treatment of severe aplastic anemia
Pharmacology
- Small molecule thrombopoietin (TPO) receptor agonist
- Interacts with the transmembrane domain of the human TPO-receptor
- Induces proliferation and differentiation from bone marrow progenitor cells
- Increases platelet production
Dosage & Administration
- Route of administration: Oral
- Should be taken without a meal or with a meal low in calcium
- Dosage tailored for different conditions and patient demographics
- Includes specific doses for persistent or chronic immune thrombocytopenia, chronic hepatitis C associated thrombocytopenia, severe aplastic anemia, and refractory severe aplastic anemia
Interaction
- Requires time gap before or after taking medications or products containing polyvalent cations
- Requires time gap before or after consuming calcium-rich foods
Contraindications
- Known hypersensitivity to eltrombopag or any components of the product
Side Effects
- Common side effects include anemia, nausea, pyrexia, ALT increased, cough, fatigue, headache, and diarrhea
Pregnancy & Lactation
- Insufficient data to assess drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes
- Not recommended during breastfeeding due to potential for serious adverse reactions in a breastfed child
Precautions & Warnings
- Increased risk of hepatic decompensation in patients with chronic hepatitis C
- Increased risk of death and progression of myelodysplastic syndromes to acute myeloid leukemia
- Possible occurrence of portal vein thrombosis in patients with chronic liver disease receiving eltrombopag
- Regular monitoring of liver function and platelet counts
Use in Special Populations
- Safety and efficacy not established in pediatric patients below the age of 1 year with ITP
- Safety and efficacy not established in pediatric patients with thrombocytopenia associated with chronic hepatitis C and refractory severe aplastic anemia
Overdose Effects
- Excessive increase in platelet counts
- May result in thrombotic or thromboembolic complications
- Consider oral administration of metal cation containing preparation to chelate eltrombopag and limit absorption
Therapeutic Class
Haemostatic drugs
Storage Conditions
Store in a cool (below 25°C) and dry place protected from light. Keep away from the reach of children